Silvercrest Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.09M Sell
67,496
-36,653
-35% -$2.14M 0.03% 452
2025
Q4
$5.62M Buy
104,149
+223
+0.2% +$10.7K 0.04% 414
2025
Q3
$4.69M Sell
103,926
-920
-0.9% -$43K 0.03% 434
2025
Q2
$4.85M Sell
104,846
-11,597
-10% -$569K 0.03% 434
2025
Q1
$7.1M Buy
116,443
+4,687
+4% +$273K 0.05% 348
2024
Q4
$6.32M Buy
111,756
+50
+0% +$2.79K 0.04% 372
2024
Q3
$5.78M Sell
111,706
-589
-0.5% -$27.6K 0.04% 358
2024
Q2
$4.66M Buy
112,295
+525
+0.5% +$23.5K 0.03% 410
2024
Q1
$6.06M Sell
111,770
-387
-0.3% -$19.7K 0.04% 357
2023
Q4
$5.75M Sell
112,157
-1,055
-0.9% -$55.4K 0.04% 352
2023
Q3
$6.57M Buy
113,212
+14
+0% +$858 0.05% 302
2023
Q2
$7.24M Buy
113,198
+12
+0% +$805 0.05% 301
2023
Q1
$7.84M Sell
113,186
-739
-0.6% -$52.1K 0.06% 269
2022
Q4
$8.2M Buy
113,925
+1,193
+1% +$90K 0.06% 254
2022
Q3
$8.01M Sell
112,732
-200
-0.2% -$14.5K 0.07% 253
2022
Q2
$8.7M Sell
112,932
-3,076
-3% -$234K 0.07% 248
2022
Q1
$8.47M Sell
116,008
-4,011
-3% -$269K 0.06% 283
2021
Q4
$7.48M Sell
120,019
-25,833
-18% -$1.52M 0.05% 308
2021
Q3
$8.63M Sell
145,852
-12,374
-8% -$815K 0.06% 290
2021
Q2
$10.6M Buy
158,226
+40
+0% +$2.61K 0.07% 265
2021
Q1
$9.99M Sell
158,186
-17,252
-10% -$1.07M 0.07% 260
2020
Q4
$10.9M Sell
175,438
-2,898
-2% -$178K 0.08% 232
2020
Q3
$10.8M Sell
178,336
-364
-0.2% -$21.9K 0.09% 220
2020
Q2
$10.5M Sell
178,700
-7,408
-4% -$443K 0.09% 204
2020
Q1
$10.4M Sell
186,108
-7,387
-4% -$452K 0.11% 188
2019
Q4
$12.4M Buy
193,495
+27,287
+16% +$1.56M 0.1% 210
2019
Q3
$8.43M Buy
166,208
+1,010
+0.6% +$47.5K 0.07% 239
2019
Q2
$7.49M Sell
165,198
-325
-0.2% -$15.1K 0.07% 194
2019
Q1
$7.9M Buy
165,523
+2,328
+1% +$116K 0.08% 188
2018
Q4
$8.48M Sell
163,195
-500
-0.3% -$26.9K 0.09% 180
2018
Q3
$10.2M Sell
163,695
-6,369
-4% -$378K 0.09% 179
2018
Q2
$9.41M Sell
170,064
-6,075
-3% -$328K 0.09% 189
2018
Q1
$11.1M Sell
176,139
-8,350
-5% -$537K 0.11% 171
2017
Q4
$11.3M Buy
184,489
+8,030
+5% +$502K 0.11% 175
2017
Q3
$11.2M Sell
176,459
-4,572
-3% -$267K 0.11% 171
2017
Q2
$10.1M Sell
181,031
-1,056
-0.6% -$57.5K 0.11% 176
2017
Q1
$9.9M Sell
182,087
-37,883
-17% -$2.08M 0.11% 172
2016
Q4
$12.9M Sell
219,970
-34,473
-14% -$1.88M 0.14% 149
2016
Q3
$13.7M Sell
254,443
-314
-0.1% -$20.2K 0.16% 141
2016
Q2
$18.7M Buy
254,757
+132
+0.1% +$9.33K 0.24% 121
2016
Q1
$16.3M Sell
254,625
-3,150
-1% -$199K 0.22% 124
2015
Q4
$17.7M Sell
257,775
-9,004
-3% -$595K 0.25% 118
2015
Q3
$15.8M Sell
266,779
-371
-0.1% -$23.5K 0.24% 119
2015
Q2
$17.8M Buy
267,150
+18,067
+7% +$1.19M 0.24% 121
2015
Q1
$16.1M Buy
249,083
+3,030
+1% +$190K 0.23% 123
2014
Q4
$14.5M Buy
246,053
+1,996
+0.8% +$113K 0.21% 126
2014
Q3
$12.5M Sell
244,057
-1,400
-0.6% -$69.9K 0.19% 137
2014
Q2
$11.9M Sell
245,457
-14,600
-6% -$719K 0.18% 137
2014
Q1
$13.5M Sell
260,057
-8,300
-3% -$442K 0.22% 126
2013
Q4
$14.3M Sell
268,357
-22,295
-8% -$1.14M 0.24% 122
2013
Q3
$13.5M Buy
290,652
+79,771
+38% +$3.5M 0.26% 111
2013
Q2
$9.43M Buy
+210,881
New +$9.16M 0.2% 126

Other funds holding BMY

Silvercrest Asset Management's BMY Position: Q1 2026 in Review

Silvercrest Asset Management reduced its Bristol-Myers Squibb (BMY) stake by 35% in Q1 2026, selling an estimated $2.14M and leaving 67,496 shares worth $4.09M. The position accounts for 0.03% of the portfolio, ranked #452.

Silvercrest Asset Management first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $18.7M in Q2 2016. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Silvercrest Asset Management held 67,496 shares of Bristol-Myers Squibb worth $4.09M as of Q1 2026.
  • Silvercrest Asset Management sold 36,653 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.14M.
  • Bristol-Myers Squibb made up 0.03% of Silvercrest Asset Management's portfolio in Q1 2026, its #452 holding.
  • Silvercrest Asset Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Silvercrest Asset Management's Bristol-Myers Squibb position peaked at $18.7M in Q2 2016.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.